HC Wainwright downgraded shares of BeyondSpring (NASDAQ:BYSI) from a buy rating to a neutral rating in a research report released on Monday, Analyst Ratings Network reports.
Several other brokerages have also issued reports on BYSI. Bank of America assumed coverage on shares of BeyondSpring in a research report on Monday, January 11th. They set a buy rating and a $25.00 target price for the company. Zacks Investment Research lowered shares of BeyondSpring from a buy rating to a hold rating in a research report on Thursday, January 21st. Finally, Evercore ISI assumed coverage on shares of BeyondSpring in a research report on Monday, December 28th. They set an outperform rating and a $30.00 target price for the company.
BYSI stock opened at $10.27 on Monday. The firm has a 50 day moving average of $12.43 and a 200-day moving average of $13.01. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.09. BeyondSpring has a 12 month low of $9.83 and a 12 month high of $21.50. The firm has a market capitalization of $401.99 million, a P/E ratio of -5.03 and a beta of 0.60.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia.
Featured Story: Understanding the different types of bonds
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.